静脉大剂量维生素C对脓毒症患者死亡率的影响:随机对照试验的系统评价与Meta分析
主要终点短期死亡率(28天、30天或住院死亡率)无显著降低(RR 0.88,95%CI 0.73-1.06,P=0.18)。次要终点显示血管升压药使用时间显著缩短(SMD -0.35,95%CI -0.63至-0.07)且72-96小时SOFA评分下降更显著(SMD -0.20,95%CI -0.32至-0.08)。不良事件罕见,一项研究报道高钠血症相关。临床意义在于不推荐以降低死亡率为目的常规使用,但可能有助于缩短升压药依赖和改善器官功能。
要点
- 成人脓毒症患者静脉大剂量维生素C未显著降低短期死亡率(RR 0.88,95%CI 0.73-1.06,P=0.18)。
- 静脉大剂量维生素C显著缩短血管升压药使用时间(SMD -0.35,95%CI -0.63至-0.07,P<0.01)。
- 静脉大剂量维生素C组72-96小时SOFA评分下降更显著(SMD -0.20,95%CI -0.32至-0.08,P<0.01)。
- 不良事件罕见,一项研究报道高钠血症显著相关;大剂量维生素C被认为相对安全。
- 不推荐以降低死亡率为唯一目的常规使用静脉大剂量维生素C治疗脓毒症。
适用人群与场景
- 年龄≥18岁的脓毒症患者,接受静脉大剂量维生素C联合标准治疗或仅标准治疗。
诊断标准与关键阈值
- 纳入标准:随机对照试验;脓毒症患者年龄≥18岁;接受静脉大剂量维生素C联合标准治疗或标准治疗。
- 主要终点短期死亡率定义为28天、30天或住院死亡率。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径频次或疗程。
红旗征与不能漏的情况
- 一项研究报道静脉大剂量维生素C与高钠血症显著相关。
研究设计与关键结果
- 静脉大剂量维生素C未显著降低短期死亡率(RR 0.88,95%CI 0.73-1.06,P=0.18,I²=29%)。
- 静脉大剂量维生素C显著缩短血管升压药使用时间(SMD -0.35,95%CI -0.63至-0.07,P<0.01,I²=80%)。
- 静脉大剂量维生素C组72-96小时SOFA评分下降更显著(SMD -0.20,95%CI -0.32至-0.08,P<0.01,I²=16%)。
- 不良事件罕见,一项研究报道高钠血症显著相关,大剂量维生素C被认为相对安全。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 局限性:原文未提及具体证据等级或推荐强度;异质性方面血管升压药使用时间I²=80%,SOFA评分I²=16%。
对床旁实践的改变
- 不推荐以降低短期死亡率为目的对脓毒症患者常规使用静脉大剂量维生素C。
- 可考虑静脉大剂量维生素C用于缩短血管升压药使用时间和改善72-96小时SOFA评分,但需注意高钠血症风险。
- 适用人群为年龄≥18岁脓毒症患者;不适用人群原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials to investigate whether IV high-dose vitamin C improves the short-term mortality of patients with sepsis.
DESIGN: This study is a systematic review and meta-analysis of randomized controlled trials. We searched EMBASE, the Cochrane Central Register of Controlled Trials, and MEDLINE for randomized controlled trials that met inclusion criteria. The protocol was registered at the University hospital Medical Information Network Clinical Trials Registry (UMIN000040528). All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as 28-day, 30-day, or in-hospital mortality.
PATIENTS: Two authors independently evaluated the following eligibility criteria: 1) randomized controlled trial, 2) patients with sepsis aged ≥18 years, and 3) received intravenous high-dose vitamin C in addition to standard of care, or standard of care alone. Then, two authors independently extracted the selected patient and study characteristics and outcomes from studies that met above eligibility criteria.
MEASUREMENTS AND MAIN RESULTS: Eleven randomized controlled trials (n = 1,737 patients) were included in this meta-analysis. High-dose IV vitamin C was not associated with a significantly lower short-term mortality (risk ratio, 0.88; 95% CI, 0.73-1.06; p = 0.18; I2 = 29%) but was associated with a significantly shorter duration of vasopressor use (standardized mean difference, -0.35; 95% CI, -0.63 to -0.07; p < 0.01; I2 = 80%) and a significantly greater decline in the Sequential Organ Failure Assessment score at 72-96 hours (standardized mean difference, -0.20; 95% CI, -0.32 to -0.08; p < 0.01; I2 = 16%). One study reported significant association with hypernatremia, but adverse effects were rare, and high-dose vitamin C is deemed relatively safe.
CONCLUSIONS: In this meta-analysis, the use of IV high-dose vitamin C in patients with sepsis was not associated with lower short-term mortality although it was associated with significantly shorter duration of vasopressor use and greater decline in the Sequential Organ Failure Assessment score at 72-96 hours.
参考来源
- Sato R, Hasegawa D, Prasitlumkum N, et al. Effect of IV High-Dose Vitamin C on Mortality in Patients With Sepsis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Crit Care Med. 2021. PMID: 34495877. doi:10.1097/CCM.0000000000005263
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。